A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Bone Neoplasms
/ secondary
Breast Neoplasms
/ diagnostic imaging
Carcinoma, Lobular
/ diagnostic imaging
Female
Fluorodeoxyglucose F18
Humans
Magnetic Resonance Imaging
/ methods
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
Whole Body Imaging
/ methods
Breast neoplasms
Carcinoma lobular
Diffusion magnetic resonance imaging
Magnetic resonance imaging
Whole body imaging
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
04
10
2021
accepted:
04
03
2022
revised:
02
03
2022
pubmed:
7
4
2022
medline:
19
8
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Invasive lobular breast carcinomas (ILC) account for approximately 15% of breast cancer diagnoses. They can be difficult to diagnose both clinically and radiologically, due to their infiltrative growth pattern. The pattern of metastasis of ILC is unusual, with spread to the serosal surfaces (pleura and peritoneum), retroperitoneum and gastrointestinal (GI)/genitourinary (GU) tracts and a higher rate of leptomeningeal spread than IDC. Routine staging and response assessment with computed tomography (CT) can be undertaken quickly and measurements can be reproduced easily, but this is challenging with metastatic ILC as bone-only/bone-predominant patterns are frequently seen and assessment of the disease status is limited in these scenarios. Functional imaging such as whole-body MRI (WBMRI) allows the assessment of bone and soft tissue disease by providing functional information related to differences in cellular density between malignant and benign tissues. A number of recent studies have shown that WBMRI can detect additional sites of disease in metastatic breast cancer (MBC), resulting in a change in systemic anti-cancer therapy. Although WBMRI and fluorodeoxyglucose-positron-emission tomography-computed tomography (FDG-PET/CT) have a comparable performance in the assessment of MBC, WBMRI can be particularly valuable as a proportion of ILC are non-FDG-avid, resulting in the underestimation of the disease extent. In this review, we explore the added value of WBMRI in the evaluation of metastatic ILC and compare it with other imaging modalities such as CT and FDG-PET/CT. We also discuss the spectrum of WBMRI findings of the different metastatic sites of ILC with CT and FDG-PET/CT correlation. KEY POINTS: • ILC has an unusual pattern of spread compared to IDC, with metastases to the peritoneum, retroperitoneum and GI and GU tracts, but the bones and liver are the commonest sites. • WBMRI allows functional assessment of metastatic disease, particularly in bone-only and bone-predominant metastatic cancers such as ILC where evaluation with CT can be challenging and limited. • WBMRI can detect more sites of disease compared with CT, can reveal disease progression earlier and provides the opportunity to change ineffective systemic treatment sooner.
Identifiants
pubmed: 35384456
doi: 10.1007/s00330-022-08714-6
pii: 10.1007/s00330-022-08714-6
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6514-6525Informations de copyright
© 2022. The Author(s), under exclusive licence to European Society of Radiology.
Références
Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:632–637
Fisher ER, Gregorio RM, Fisher B et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36:1–85. https://doi.org/10.1002/1097-0142(197507)36:1<1::aid-cncr2820360102>3.0.co;2-4
doi: 10.1002/1097-0142(197507)36:1<1::aid-cncr2820360102>3.0.co;2-4
pubmed: 173455
Hanby AM, Hughes TA (2008) In situ and invasive lobular neoplasia of the breast. Histopathology 52:58–66. https://doi.org/10.1111/j.1365-2559.2007.02891.x
doi: 10.1111/j.1365-2559.2007.02891.x
pubmed: 18171417
Harris M, Howell A, Chrissohou M et al (1984) A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 50:23–30. https://doi.org/10.1038/bjc.1984.135
doi: 10.1038/bjc.1984.135
pubmed: 6331484
pmcid: 1976917
Lamovec J, Bračkko M (1991) Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48:28–33. https://doi.org/10.1002/jso.2930480106
doi: 10.1002/jso.2930480106
pubmed: 1653879
Winston CB, Hadar O, Teitcher JB et al (2000) Metastatic lobular carcinoma of the breast: patterns of spread in the chest, abdomen, and pelvis on CT. AJR Am J Roentgenol 175:795–800. https://doi.org/10.2214/ajr.175.3.1750795
Ferlicot S, Vincent-Salomon A, Médioni J et al (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 40:336–341. https://doi.org/10.1016/j.ejca.2003.08.007
doi: 10.1016/j.ejca.2003.08.007
pubmed: 14746850
Chen Z, Yang J, Li S et al (2017) Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One 12:e0182397. https://doi.org/10.1371/journal.pone.0182397
doi: 10.1371/journal.pone.0182397
pubmed: 28863134
pmcid: 5580913
Watanabe J, Nakamoto S, Sugino T (2021) The real-world outcomes of patients with advanced invasive lobular carcinoma of the breast compared with invasive ductal carcinoma: a review at a single institution. Anticancer Res 41:4619. https://doi.org/10.21873/anticanres.15275
doi: 10.21873/anticanres.15275
pubmed: 34475090
The Royal College of Radiologists (2019) Guidance on screening and symptomatic breast imaging, Fourth edn Clinical Radiology The Royal College of Radiologists
Miles A, Evans RE, Halligan S et al (2020) Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancer. J Med Imaging Radiat Oncol 64:537–545. https://doi.org/10.1111/1754-9485.13038
doi: 10.1111/1754-9485.13038
pubmed: 32410378
pmcid: 8425331
Pawlyn C, Fowkes L, Otero S et al (2016) Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 30:1446–1448. https://doi.org/10.1038/leu.2015.338
doi: 10.1038/leu.2015.338
pubmed: 26648535
pmcid: 4895156
Oliveri S, Paola P, Silvia P et al (2018) Investigating cancer patient acceptance of whole body MRI. Clin Imaging 52:246–251. https://doi.org/10.1016/j.clinimag.2018.08.004
doi: 10.1016/j.clinimag.2018.08.004
pubmed: 30170274
Chantry A, Kazmi M, Barrington S et al (2017) Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178:380–393. https://doi.org/10.1111/bjh.14827
doi: 10.1111/bjh.14827
pubmed: 28677897
Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5–13. https://doi.org/10.1148/radiol.2019181949
doi: 10.1148/radiol.2019181949
pubmed: 30806604
Padhani AR, Lecouvet FE, Tunariu N et al (2017) Metastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033
doi: 10.1016/j.eururo.2016.05.033
pubmed: 27317091
pmcid: 5176005
Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124:142–155. https://doi.org/10.1038/s41416-020-01175-y
doi: 10.1038/s41416-020-01175-y
pubmed: 33250512
Ji L, Cheng L, Zhu X, Gao Y, Fan L, Wang Z (2021) Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer 21:238. https://doi.org/10.1186/s12885-021-07968-5
Padhani AR, Koh DM (2011) Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19:181–209. https://doi.org/10.1016/j.mric.2010.10.004
doi: 10.1016/j.mric.2010.10.004
pubmed: 21129641
Fletcher BD, Wall JE, Hanna SL (1993) Effect of hematopoietic growth factors on MR images of bone marrow in children undergoing chemotherapy. Radiology 189:745–751. https://doi.org/10.1148/radiology.189.3.7694312
doi: 10.1148/radiology.189.3.7694312
pubmed: 7694312
Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, deBono JS (2014) Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging 39:1049–1078. https://doi.org/10.1002/jmri.24548
Cui Y, Zhang X-P, Sun Y-S et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900. https://doi.org/10.1148/radiol.2483071407
doi: 10.1148/radiol.2483071407
pubmed: 18710982
Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837. https://doi.org/10.1593/neo.03343
Godinho MV, Lopes FPPL, Costa FM (2018) Whole-body magnetic resonance imaging for the assessment of metastatic breast cancer. Cancer Manag Res 10:6743–6756. https://doi.org/10.2147/CMAR.S167924
doi: 10.2147/CMAR.S167924
pubmed: 30584368
pmcid: 6289208
Woolf DK, Padhani AR, Makris A (2015) Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol 26:1048–1057. https://doi.org/10.1093/annonc/mdu558
doi: 10.1093/annonc/mdu558
pubmed: 25471332
Michielsen K, Vergote I, Op De Beeck K et al (2014) Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol 24:889–901. https://doi.org/10.1007/s00330-013-3083-8
doi: 10.1007/s00330-013-3083-8
pubmed: 24322510
van ’t Sant I, Engbersen MP, Bhairosing PA, et al (2020) Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol 30:3101–3112. https://doi.org/10.1007/s00330-019-06524-x
Zugni F, Ruju F, Pricolo P et al (2018) The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer. PLoS One 13:1–16. https://doi.org/10.1371/journal.pone.0205251
doi: 10.1371/journal.pone.0205251
DiPiro PJ, Tirumani SH, Cruz GP et al (2019) Lobular breast cancer: patterns of intraabdominal metastatic spread on imaging and prognostic significance. Abdom Radiol (NY) 44:362–369. https://doi.org/10.1007/s00261-018-1722-x
Kyriazi S, Collins DJ, Morgan VA et al (2010) Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics 30:1269–1285. https://doi.org/10.1148/rg.305105073
doi: 10.1148/rg.305105073
pubmed: 20833850
Brown DL, Zou KH, Tempany CM et al (2001) Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study. Radiology 219:213–218. https://doi.org/10.1148/radiology.219.1.r01ap28213
doi: 10.1148/radiology.219.1.r01ap28213
pubmed: 11274559
He H, Gonzalez A, Robinson E, Yang WT (2014) Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast. AJR Am J Roentgenol 202:1140–1148. https://doi.org/10.2214/AJR.13.11156
Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031–1039. https://doi.org/10.1016/j.ejca.2006.01.026
doi: 10.1016/j.ejca.2006.01.026
pubmed: 16616487
Yang HL, Liu T, Wang XM et al (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617. https://doi.org/10.1007/s00330-011-2221-4
doi: 10.1007/s00330-011-2221-4
pubmed: 21887484
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Sugihara T, Koizumi M, Koyama M et al (2017) Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med 31:719–725. https://doi.org/10.1007/s12149-017-1202-3
doi: 10.1007/s12149-017-1202-3
pubmed: 28864931
pmcid: 5691120
Hamaoka T, Costelloe CM, Madewell JE et al (2010) Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102:651–657. https://doi.org/10.1038/sj.bjc.6605546
doi: 10.1038/sj.bjc.6605546
pubmed: 20104228
pmcid: 2837571
Cook GJR, Goh V (2020) Molecular Imaging of Bone Metastases and Their Response to Therapy. J Nucl Med 61:799–806. https://doi.org/10.2967/jnumed.119.234260
doi: 10.2967/jnumed.119.234260
pubmed: 32245899
Palmedo H, Marx C, Ebert A et al (2014) Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 41:59–67. https://doi.org/10.1007/s00259-013-2532-6
doi: 10.1007/s00259-013-2532-6
pubmed: 23974666
Savelli G, Maffioli L, Maccauro M, et al (2001) Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 45:27–37
Vogel CL, Schoenfelder J, Shemano I et al (1995) Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13:1123–1128. https://doi.org/10.1200/JCO.1995.13.5.1123
doi: 10.1200/JCO.1995.13.5.1123
pubmed: 7537797
Rong J, Wang S, Ding Q et al (2013) Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 22:86–91. https://doi.org/10.1016/j.suronc.2013.01.002
doi: 10.1016/j.suronc.2013.01.002
pubmed: 23726506
Shie P, Cardarelli R, Brandon D et al (2008) Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33:97–101. https://doi.org/10.1097/RLU.0b013e31815f23b7
doi: 10.1097/RLU.0b013e31815f23b7
pubmed: 18209527
Dashevsky BZ, Goldman DA, Parsons M et al (2015) Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging 42:1666–1673. https://doi.org/10.1007/s00259-015-3080-z
doi: 10.1007/s00259-015-3080-z
pubmed: 25971426
pmcid: 4558334
Avril N, Rosé CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 18:3495–3502. https://doi.org/10.1200/JCO.2000.18.20.3495
doi: 10.1200/JCO.2000.18.20.3495
pubmed: 11032590
Bos R, van Der Hoeven JJM, van Der Wall E et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387. https://doi.org/10.1200/JCO.2002.20.2.379
doi: 10.1200/JCO.2002.20.2.379
pubmed: 11786564
Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949. https://doi.org/10.1007/s00330-006-0361-8
doi: 10.1007/s00330-006-0361-8
pubmed: 16951929
Kosmin M, Padhani AR, Gogbashian A et al (2020) Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297:622–629. https://doi.org/10.1148/radiol.2020192683
doi: 10.1148/radiol.2020192683
pubmed: 33078998
Botsikas D, Bagetakos I, Picarra M et al (2019) What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer? Eur Radiol 29:1787–1798. https://doi.org/10.1007/s00330-018-5720-8
doi: 10.1007/s00330-018-5720-8
pubmed: 30267154
Bruckmann NM, Sawicki LM, Kirchner J et al (2020) Prospective evaluation of whole-body MRI and (18)F-FDG PET/MRI in N and M staging of primary breast cancer patients. Eur J Nucl Med Mol Imaging 47:2816–2825. https://doi.org/10.1007/s00259-020-04801-2
doi: 10.1007/s00259-020-04801-2
pubmed: 32333068
pmcid: 7567721
Bruckmann NM, Kirchner J, Umutlu L et al (2021) Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 31:8714–8724. https://doi.org/10.1007/s00330-021-07956-0
doi: 10.1007/s00330-021-07956-0
pubmed: 33912991
pmcid: 8523471
Husseini JS, Amorim BJ, Torrado-Carvajal A et al (2021) An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. Eur J Nucl Med Mol Imaging 48:1522–1537. https://doi.org/10.1007/s00259-021-05198-2
doi: 10.1007/s00259-021-05198-2
pubmed: 33619599
pmcid: 8240455
Kosmin M, Makris A, Joshi PV et al (2017) The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer 77:109–116. https://doi.org/10.1016/j.ejca.2017.03.001
doi: 10.1016/j.ejca.2017.03.001
pubmed: 28390297
Oliai C, Douek ML, Rhoane C et al (2019) Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Res Treat 177:409–417. https://doi.org/10.1007/s10549-019-05311-y
doi: 10.1007/s10549-019-05311-y
pubmed: 31175499
pmcid: 6664810
Sharma B, Martin A, Zerizer I (2013) Positron emission tomography-computed tomography in liver imaging. Seminars in Ultrasound, CT and MRI 34:66–80. https://doi.org/10.1053/j.sult.2012.11.006
doi: 10.1053/j.sult.2012.11.006
pubmed: 23395319
Hogan MP, Goldman DA, Dashevsky B et al (2015) Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med 56:1674–1680. https://doi.org/10.2967/jnumed.115.161455
doi: 10.2967/jnumed.115.161455
pubmed: 26294295
Tunariu N, Blackledge M, Messiou C et al (2020) What’s new for clinical whole-body MRI (WB-MRI) in the 21st century. Br J Radiol 93:20200562. https://doi.org/10.1259/bjr.20200562
doi: 10.1259/bjr.20200562
pubmed: 32822545
pmcid: 8519652
Bonnier P, Romain S, Dilhuydy JM et al (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 72:720–727. https://doi.org/10.1002/(sici)1097-0215(19970904)72:5<720::aid-ijc3>3.0.co;2-u
doi: 10.1002/(sici)1097-0215(19970904)72:5<720::aid-ijc3>3.0.co;2-u
pubmed: 9311584
Montagna E, Peccatori F, Petralia G et al (2014) Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report. Breast 23:295–296. https://doi.org/10.1016/j.breast.2014.01.012
doi: 10.1016/j.breast.2014.01.012
pubmed: 24529906
Peccatori FA, Codacci-Pisanelli G, Del Grande M et al (2017) Whole body MRI for systemic staging of breast cancer in pregnant women. Breast 35:177–181. https://doi.org/10.1016/j.breast.2017.07.014
Han SN, Amant F, Michielsen K et al (2018) Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. Eur Radiol 28:1862–1874. https://doi.org/10.1007/s00330-017-5126-z
doi: 10.1007/s00330-017-5126-z
pubmed: 29218610
Medicines and Healthcare Products Regulatory Agency (2021) Safety guidelines for magnetic resonance imaging equipment in clinical use. Accessed 8 Jul 2021
Ray JG, Vermeulen MJ, Bharatha A et al (2016) Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 316:952–961. https://doi.org/10.1001/jama.2016.12126
doi: 10.1001/jama.2016.12126
pubmed: 27599330
Regier M, Schwarz D, Henes FO et al (2011) Diffusion-weighted MR-imaging for the detection of pulmonary nodules at 1.5 Tesla: intraindividual comparison with multidetector computed tomography. J Med Imaging Radiat Oncol 55:266–274. https://doi.org/10.1111/j.1754-9485.2011.02263.x
doi: 10.1111/j.1754-9485.2011.02263.x
pubmed: 21696559
Paruthikunnan SM, Kadavigere R, Karegowda LH (2017) Accuracy of whole-body dwi for metastases screening in a diverse group of malignancies: comparison with conventional cross-sectional imaging and nuclear scintigraphy. AJR Am J Roentgenol 209:477–490. https://doi.org/10.2214/AJR.17.17829
Antoch G, Vogt FM, Freudenberg LS, Goehde SC (2016) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206
Koh D-M, Blackledge M, Padhani AR et al (2012) Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 199:252–262. https://doi.org/10.2214/AJR.11.7866
doi: 10.2214/AJR.11.7866
pubmed: 22826385